Literature DB >> 27280619

Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.

Michael P Broderick1, Sandra Romero-Steiner2, Gowrisankar Rajam2, Scott E Johnson2, Andrea Milton2, Ellie Kim2, Lisa J Choi2, Jennifer M Radin3, Daniel S Schmidt2, George M Carlone2, Nancy Messonnier2, Dennis J Faix3.   

Abstract

Immunological responses to vaccination can differ depending on whether the vaccine is given alone or with other vaccines. This study was a retrospective evaluation of the immunogenicity of a tetravalent meningococcal conjugate vaccine for serogroups A, C, W, and Y (MenACWY) administered alone (n = 41) or concomitantly with other vaccines (n = 279) to U.S. military personnel (mean age, 21.6 years) entering the military between 2006 and 2008. Concomitant vaccines included tetanus/diphtheria (Td), inactivated polio vaccine (IPV), hepatitis vaccines, and various influenza vaccines, among others; two vaccine groups excluded Tdap and IPV. Immune responses were evaluated in baseline and postvaccination sera for Neisseria meningitidis serogroups C and Y 1 to 12 months (mean, 4.96 months) following vaccination. Functional antibodies were measured by using a serum bactericidal antibody assay with rabbit complement (rSBA) and by measurement of serogroup-specific immunoglobulin G (IgG) antibodies. The percentage of vaccinees reaching threshold levels (IgG concentration in serum, ≥2 μg/ml; rSBA titer, ≥8) corresponding to an immunologic response was higher postvaccination than at baseline (P < 0.001). Administration of MenACWY along with other vaccines was associated with higher geometric means of IgG concentrations and rSBA titers than those measured 4.60 months after a single dose of MenACWY. In addition, higher percentages of vaccinees reached the immunological threshold (range of odds ratios [ORs], 1.5 to 21.7) and more of them seroconverted (OR range, 1.8 to 4.8) when MenACWY was administered with any other vaccine than when administered alone. Additional prospective randomized clinical trials are needed to confirm the observed differences among groups in the immune response to MenACWY when given concomitantly with other vaccines to U.S. military personnel.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27280619      PMCID: PMC4979175          DOI: 10.1128/CVI.00267-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  Assignment of additional anticapsular antibody concentrations to the Neisseria meningitidis group A, C, Y, and W-135 meningococcal standard reference serum CDC1992.

Authors:  Cheryl M Elie; Patricia K Holder; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

Authors:  Harry Keyserling; Thomas Papa; Katalin Koranyi; Robert Ryall; Ehab Bassily; Michael J Bybel; Kevin Sullivan; Gregory Gilmet; Al Reinhardt
Journal:  Arch Pediatr Adolesc Med       Date:  2005-10

Review 3.  Review of diphtheria, tetanus and pertussis vaccines in clinical development.

Authors:  Nicholas R E Kitchin
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

4.  Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age.

Authors:  E Mills; R Gold; J Thipphawong; L Barreto; R Guasparini; W Meekison; L Cunning; M Russell; D Harrison; M Boyd; F Xie
Journal:  Vaccine       Date:  1998-04       Impact factor: 3.641

5.  Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.

Authors: 
Journal:  Pediatrics       Date:  2005-07-01       Impact factor: 7.124

Review 6.  Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.

Authors:  D J West; G P Rabalais; B Watson; H L Keyserling; H Matthews; T M Hesley
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

7.  Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.

Authors:  Nick Andrews; Ray Borrow; Elizabeth Miller
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

8.  A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age.

Authors:  Nicholas Kitchin; Joanna Southern; Rhonwen Morris; Fabienne Hemme; Keith Cartwright; Michael Watson; Elizabeth Miller
Journal:  Vaccine       Date:  2006-02-21       Impact factor: 3.641

9.  Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay.

Authors:  L L Gheesling; G M Carlone; L B Pais; P F Holder; S E Maslanka; B D Plikaytis; M Achtman; P Densen; C E Frasch; H Käyhty
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

10.  Molecular signatures of antibody responses derived from a systems biology study of five human vaccines.

Authors:  Shuzhao Li; Nadine Rouphael; Sai Duraisingham; Sandra Romero-Steiner; Scott Presnell; Carl Davis; Daniel S Schmidt; Scott E Johnson; Andrea Milton; Gowrisankar Rajam; Sudhir Kasturi; George M Carlone; Charlie Quinn; Damien Chaussabel; A Karolina Palucka; Mark J Mulligan; Rafi Ahmed; David S Stephens; Helder I Nakaya; Bali Pulendran
Journal:  Nat Immunol       Date:  2013-12-15       Impact factor: 25.606

View more
  3 in total

1.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

Review 2.  Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence.

Authors:  Justine Alderfer; Amit Srivastava; Raul Isturiz; Cynthia Burman; Judith Absalon; Johannes Beeslaar; John Perez
Journal:  Hum Vaccin Immunother       Date:  2019-04-19       Impact factor: 3.452

3.  Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization.

Authors:  Claudia Ferlito; Vincenzo Visco; Roberto Biselli; Maria Sofia Cattaruzza; Giulia Carreras; Gerardo Salerno; Florigio Lista; Maria Rosaria Capobianchi; Concetta Castilletti; Daniele Lapa; Guido Antonelli; Massimo Gentile; Maurizio Sorice; Gloria Riitano; Giuseppe Lucania; Valeria Riccieri; Fabrizio Mainiero; Antonio Angeloni; Marco Lucarelli; Giampiero Ferraguti; Alberto Autore; Marco Lastilla; Simonetta Salemi; Michela Ileen Biondo; Andrea Picchianti-Diamanti; Sara Caporuscio; Raffaela Teloni; Sabrina Mariotti; Roberto Nisini; Raffaele D'Amelio
Journal:  Biomedicines       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.